



Universiteit  
Leiden  
The Netherlands

## **Regulation of actomyosin contraction as a driving force of invasive lobular breast cancer**

Schipper, K.

### **Citation**

Schipper, K. (2020, December 3). *Regulation of actomyosin contraction as a driving force of invasive lobular breast cancer*. Retrieved from <https://hdl.handle.net/1887/138484>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/138484>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/138484> holds various files of this Leiden University dissertation.

**Author:** Schipper, K.

**Title:** Regulation of actomyosin contraction as a driving force of invasive lobular breast cancer

**Issue date:** 2020-12-03

# Rebalancing of actomyosin contractility enables mammary tumor formation upon loss of E-cadherin

3

Koen Schipper<sup>1</sup>, Danielle Seinsträ<sup>1</sup>, Anne Paulien Drenth<sup>1</sup>, Eline van der Burg<sup>1</sup>, Veronika Ramovs<sup>2</sup>, Arnoud Sonnenberg<sup>2</sup>, Jacco van Rheenen<sup>1</sup>, Micha Nethe<sup>1,3\*</sup>, Jos Jonkers<sup>1\*</sup>

1. Division of Molecular Pathology, Onco Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  2. Division of Cell Biology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
  3. Present address: Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, Amsterdam, The Netherlands
- \* Corresponding authors: [m.nethe@sanquin.nl](mailto:m.nethe@sanquin.nl) and [jjonkers@nki.nl](mailto:jjonkers@nki.nl)

## Abstract

E-cadherin (*CDH1*) is a master regulator of epithelial cell adherence junctions and a well-established tumor suppressor in Invasive Lobular Carcinoma (ILC). Intriguingly, somatic inactivation of E-cadherin alone in mouse mammary epithelial cells (MMECs) is insufficient to induce tumor formation. Here we show that E-cadherin loss induces extrusion of luminal MMECs to the basal lamina. Remarkably, E-cadherin-deficient MMECs can breach the basal lamina but do not disseminate into the surrounding fat pad. Basal lamina components laminin and collagen IV supported adhesion and survival of E-cadherin-deficient MMECs while collagen I, the principle component of the mammary stromal micro-environment did not. We uncovered that relaxation of actomyosin contractility mediates adhesion and survival of E-cadherin-deficient MMECs on collagen I, thereby allowing ILC development. Together, these findings unmask the direct consequences of E-cadherin inactivation in the mammary gland and identify aberrant actomyosin contractility as a critical barrier to ILC formation.

## Introduction

The maintenance of epithelial cell-cell adhesion sustains organ function and prevents tissue infection and tumor development. E-cadherin (*CDH1*) is a transmembrane protein and a master regulator of the cell adherence junctions controlling cell-cell adhesion. E-cadherin is also a well-established tumor suppressor which is in general viewed to prevent tumor cell dissemination<sup>1-3</sup>. Complete loss of E-cadherin expression is a hallmark of invasive lobular carcinoma (ILC)<sup>4</sup>. ILC comprises 8-14% of all breast cancer patients, making it the 2<sup>nd</sup> most diagnosed breast cancer type worldwide<sup>5,6</sup>. Histologically, ILC is characterized by non-cohesive cells arranged in single files infiltrating the surrounding fibrous collagen-rich stroma<sup>7</sup>. The infiltrative nature of ILC often complicates surgical removal. ILCs also typically respond poorly to classical regimes of chemotherapy. To gain insight into the mechanisms underlying ILC development, we have previously developed genetically engineered mouse models that, closely resemble human ILC<sup>8,9</sup>. Mammary gland-specific inactivation of E-cadherin in combination with loss of p53 or PTEN markedly enhanced mammary tumor development thus confirming the tumor suppressive role of E-cadherin<sup>8,9</sup>. Intriguingly, somatic inactivation of E-cadherin by itself is




not sufficient to induce mammary tumor formation, but rather seems to hamper survival of mouse mammary epithelial cells<sup>8,10</sup>. In addition, genetic inactivation of E-cadherin in mammary epithelial cell lines or mouse mammary epithelial organoids does not induce single cell dissociation nor epithelial-mesenchymal transition (EMT)<sup>11,12</sup>. It remains unclear why loss of E-cadherin by itself hampers cell survival and how this limitation is circumvented during ILC development.

Here we studied the direct consequence of E-cadherin loss in murine mammary epithelial cells (MMECs) by genetic labelling and tracing of E-cadherin-deficient MMECs *in vivo*. We found that E-cadherin-deficient MMECs extrude into the fibrous stroma where they form dynamic but non-tumorigenic cell clusters that only progress to ILC upon partial relaxation of actomyosin. These findings show that actomyosin levels are critical in ILC development.

## Results

### E-cadherin loss drives cell extrusion to the basal lamina

To monitor the fate of E-cadherin-deficient MMECs *in vivo*, we generated *Wcre;Cdh1<sup>F/F</sup>;mTmG* mice in which mammary gland specific expression of Cre from the *Wap* gene promoter (*Wcre*) induces somatic inactivation of *Cdh1* (encoding E-cadherin) and GFP expression by recombination of the mTmG reporter in MMECs<sup>13,14</sup> (Fig. 1a). Cre recombinase activity, marked by GFP expression, was exclusively detected in cytokeratin-8 (CK8)-positive luminal MMECs (Fig. 1b, c). Strikingly, immunofluorescence (IF) analysis of GFP expression in 6 week old *Wcre;Cdh1<sup>F/F</sup>;mTmG* mice revealed that E-cadherin-deficient luminal MMECs massively extruded towards the basal lamina and typically resided between the layer of cytokeratin-14 (CK14)-positive myoepithelial cells and the basal stroma (Fig. 1d). Loss of functional E-cadherin in MMECs was also confirmed by dissociation of both  $\beta$ -catenin and p120-catenin from the peripheral membrane due to disruption of the E-cadherin-catenin complex as previously described (Supplementary Fig. 1a, b)<sup>12,15</sup>. Whereas most extruded luminal MMECs were detected at the basal laminal border, apoptotic E-cadherin-deficient MMECs were sporadically detected in the lumen of the mammary ducts as observed previously<sup>8,10</sup>. To monitor the fate of extruded E-cadherin-deficient MMECs, we compared mammary gland sections of three-, five and 12-month-old *Wcre;Cdh1<sup>F/F</sup>;mTmG* mice ( $n = 3$ ) to age-matched *Wcre;mTmG* mice by




**Figure 1: E-cadherin loss drives cell extrusion towards the basal lamina** (a) Schematic overview of engineered alleles in *Wcre;Cdh1<sup>FF</sup>;mTmG* mice. (b,c) Examination of GFP-positive *Wcre* activity in mammary glands of 6-week-old *Wcre;mTmG* female mice by immunofluorescence (IF) analysis ( $n = 6$ ). (b) IF staining of GFP was examined in cytokeratin 8 (CK8)-positive luminal mouse mammary epithelial cells (MMECs) and (c) cytokeratin 14 (CK14)-positive myoepithelial cells. Scale bar, 10  $\mu$ m. (d) Identification of E-cadherin inactivated MMECs by IF staining of E-cadherin, GFP, CK14 and CK8 in 6-week-old *Wcre;Cdh1<sup>FF</sup>;mTmG* female mice ( $n = 6$ ). Arrows indicate events of cell extrusion upon inactivation of E-cadherin. Scale bar, 10  $\mu$ m. (e) Immunohistochemical detection of GFP-positive E-cadherin inactivated

immunohistochemistry (IHC) (Fig. 1e). Interestingly, extruded GFP-marked E-cadherin-deficient MMECs in mammary glands of *Wcre;Cdh1<sup>F/F</sup>;mTmG* mice accumulated as small clusters of cells in the fibrous surrounding stroma. IF analysis confirmed lack of E-cadherin expression in extruded GFP-positive MMECs (Fig. 1f). Moreover, the extruded MMECs represented the majority of GFP-marked E-cadherin-deficient MMECs in *Wcre;Cdh1<sup>F/F</sup>;mTmG* mice, whereas no extrusion of GFP-positive control MMECs was observed in *Wcre;mTmG* mice (Fig. 1e, g). The clusters of extruded cells did not increase in size over time, which is in line with our previous observation that loss of E-cadherin by itself does not induce mammary tumor formation in mice (Fig. 1h)<sup>8</sup>. Finally, we did not detect any MMECs in the lumen of mammary glands at these time points, supporting previous findings that E-cadherin-deficient MMECs which extrude into the lumen of the mammary gland undergo apoptosis and are rapidly cleared<sup>8,10</sup>.

### E-cadherin loss in MMECs increases actomyosin contractility

To gain more insight into the behavior of the extruded E-cadherin-deficient MMECs in the basal mammary stroma *in situ*, we analyzed mammary glands of 3-month old *Wcre;Cdh1<sup>F/F</sup>;mTmG* mice and *Wcre;mTmG* control mice ( $n = 3$ ) by live intravital microscopy. The E-cadherin-deficient cellular clusters in *Wcre;Cdh1<sup>F/F</sup>;mTmG* mice were present alongside the entire mammary ductal tree (visualized by mTomato) and faced the surrounding mammary stroma (Fig. 2a). GFP-marked extruded E-cadherin-deficient MMECs formed tight but highly dynamic clusters of motile cells which appeared to constantly tumble around each other (Fig. 2b and Supplementary Movies 1-3). Despite their enhanced motility within these clusters, E-cadherin-deficient cells did not disseminate into the surrounding mammary stroma. Interestingly, extruded MMECs in mammary glands of *Wcre;Cdh1<sup>F/F</sup>;mTmG*

← MMECs in mammary gland sections of 3-, 4- and 6-month-old *Wcre;Cdh1<sup>F/F</sup>;mTmG* female mice and age-matched *Wcre;mTmG* control mice ( $n = 3$ ). Scale bar, 20  $\mu\text{m}$ . (f) Examination of E-cadherin expression in mammary gland sections of 3-month-old *Wcre;Cdh1<sup>F/F</sup>;mTmG* female mice and age-matched *Wcre;mTmG* control mice by IF analysis of GFP, E-cadherin, CK14 and Hoechst. Asterisk indicates area of zoom. Scale bar, 50  $\mu\text{m}$  (g) Quantification of the amount of extruded GFP positive cells in 3-month-old *Wcre;Cdh1<sup>F/F</sup>;mTmG* ( $n = 3$ ) female mice and age-matched *Wcre;mTmG* ( $n = 3$ ) control mice. Data are of 9 images per group. (h) Quantification of the average size of extruded GFP positive cell clusters in the mammary glands of *Wcre;Cdh1<sup>F/F</sup>;mTmG* mice at the ages of 3, 5 and 12 months. Data are of 3 mice per time point and 10 images per mouse. All data are depicted as mean  $\pm$  standard deviation. All  $p$ -values were calculated using an unpaired two tailed t-test. Source data are provided as a Source Data file.



**Figure 2: E-cadherin loss increases actomyosin contractility** (a) Still images derived from *in vivo* intravital imaging of the mammary gland of 8-week-old *Wcre;mTmG* and *Wcre;Cdh1<sup>F/F</sup>;mTmG* mice displaying GFP-positive Cre-switched MMECs and mTomato non-switched MMECs and stromal cells. Zooms reveal motile GFP-positive E-cadherin inactivated MMECs in *Wcre;Cdh1<sup>F/F</sup>;mTmG* mice. Scale bare, 20  $\mu$ m. (b) Quantification of the percentage of GFP-positive motile cells among *Wcre;mTmG* ( $n = 2$ ) and *Wcre;Cdh1<sup>F/F</sup>;mTmG* ( $n = 3$ ) mice. Data are of 4 and 3 images per group respectively. (c) Still image of *in vivo* intravital imaging of *Wcre;Cdh1<sup>F/F</sup>;mTmG* mice demonstrate extensive cell blebbing of GFP-positive E-cadherin inactivated MMECs. Scale bar, 10  $\mu$ m. (d) Quantification of the percentage of GFP-positive blebbing cells among *Wcre;mTmG* ( $n = 2$ ) and *Wcre;Cdh1<sup>F/F</sup>;mTmG* ( $n = 3$ ) mice. Data are of 4 and 3 images per group respectively. (e) Examination of myosin light chain (MLC) activity by IF analysis of pSer<sup>19</sup> MLC in GFP-positive E-cadherin deficient MMECs in 5 month old *Wcre;mTmG* and *Wcre;Cdh1<sup>F/F</sup>;mTmG* mice. Scale bar, 20  $\mu$ m. (f) Quantification of the amount of GFP<sup>+</sup> pSer<sup>19</sup> MLC<sup>high</sup> cells *Wcre;mTmG* ( $n = 3$ ) and *Wcre;Cdh1<sup>F/F</sup>;mTmG* ( $n = 3$ ) mice. Data are of 51 and 60 images respectively. All data are depicted as mean  $\pm$  standard deviation. All

mice were marked by extensive membrane blebbing. (Fig. 2c, d). Membrane blebbing is often seen in amoeboid migration<sup>16</sup> and apoptosis<sup>17</sup>. However we could not observe any defined form of cell movement or cell death during the time of imaging. We also did not find any cleaved caspase-3 positive apoptotic cells at the basal stromal compartment<sup>8</sup>. Since membrane blebbing typically results from elevated actomyosin contractility we next examined myosin-light chain (MLC) phosphorylation by IF imaging in mammary gland sections of *Wcre;mTmG* and *Wcre;Cdh1<sup>F/F</sup>;mTmG* mice (Fig. 2e). In normal mammary glands, luminal epithelial cells have relatively low MLC phosphorylation levels compared to myoepithelial cells. E-cadherin-deficient MMECs in the mammary fibrous stroma showed a clear increase in pMLC staining, confirming an increase in actomyosin contractility (Fig. 2e, f and Supplementary Fig. 2a). Overall these results reveal that E-cadherin-deficient MMECs that persist in the fibrous mammary stroma exhibit an increase in actomyosin contractility.


### Actomyosin relaxation enables survival upon E-cadherin loss

To study the consequences of E-cadherin loss in more detail, we isolated mammary epithelium from *Wcre;Cdh1<sup>F/F</sup>;mTmG* mice and *Wcre;mTmG* mice. Initial attempts to culture *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMECs failed as GFP-positive MMECs detached during formation of epithelial islands and were consequently lost during cell culture (Fig. 3a and Supplementary Movie 4). Since extensive cell blebbing preceded cell detachment, we hypothesized that increased actomyosin contractility, as observed *in situ*, may hamper adhesion of *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMECs. To test this hypothesis we cultured *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMECs with a ROCK inhibitor (Y-27632), which rescued their adhesion and expansion (Fig. 3a). The obtained polyclonal MMEC population, harboring both GFP-positive and GFP-negative MMECs, had decreased E-cadherin expression indicating the presence of E-cadherin negative cells (Fig 3b). Next, we derived E-cadherin proficient and -deficient subclones by picking GFP-positive MMECs in the presence of Y-27632 from *Wcre;mTmG* and *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMECs (Fig. 3c). This allowed us to examine cell adhesion of cultured E-cadherin-deficient *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMEC subclones in the presence and absence of Y-27632 (10  $\mu$ M). All E-cadherin-deficient

---

*p*-values were calculated using an unpaired two tailed t-test. Source data are provided as a Source Data file.





**Figure 3: Actomyosin relaxation enables survival upon E-cadherin loss** (a) Merged brightfield and GFP images of MMECs isolated from *Wcre;mTmG* and *Wcre;Cdh1<sup>FF</sup>;mTmG* female mice in the absence or presence of 10  $\mu$ M Y27632. Asterisks indicate areas of zoom, red dotted lines display outgrowth of E-cadherin deficient MMECs. Zooms display altered cell adhesion in the absence or presence of Y-27632 of GFP-positive E-cadherin deficient cells derived from *Wcre;Cdh1<sup>FF</sup>;mTmG* female mice. Scale bar, 50  $\mu$ m. (b) Western blot analysis of *Wcre;mTmG* and *Wcre;Cdh1<sup>FF</sup>;mTmG* MMECs stained for E-cadherin and tubulin (loading control). (c) Western blot analysis of subclones derived from the *Wcre;mTmG* and *Wcre;Cdh1<sup>FF</sup>;mTmG* MMECs stained for E-cadherin and tubulin (loading control). (d) Brightfield images of MMECs 3 hours post seeding in the absence or presence of 10  $\mu$ M Y-27632 or 10  $\mu$ M

MMEC subclones displayed extensive cell blebbing during cell adhesion (Fig. 3d). In the absence of Y-27632, E-cadherin-deficient MMECs showed reduced survival signaling and increased expression of cleaved-caspase 3 indicating the initiation of apoptosis (Fig. 3d). Inhibition of ROCK activity by Y-27632 rescued cell spreading and survival of *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMECs (Fig. 3d). To reduce actomyosin contractility downstream of ROCK we next used Blebbistatin to directly reduce myosin activity. Like ROCK inhibition by Y-27632, direct inhibition of myosin activity by blebbistatin (10 $\mu$ M) readily rescued cell adhesion of E-cadherin-deficient *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMECs (Fig. 3d). E-cadherin proficient *Wcre;mTmG* MMEC subclones did not require Y-27632 or blebbistatin to induce cell spreading but nevertheless displayed enhanced cell adhesion and survival upon inhibiting actomyosin contractility (Fig. 3d, f). Remarkably, once cell adhesion was restored, *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMECs grew significantly faster than *Wcre;mTmG* MMECs, likely due to loss of cell contact inhibition as previously reported to be controlled by E-cadherin signaling (Fig. 3f, g)<sup>18,19</sup>. To substantiate our findings, we derived polyclonal cell lines from wildtype (WT) MMECs and *Cdh1<sup>A/A</sup>* MMECs, which were produced by exposing *Cdh1<sup>F/F</sup>* MMECs to a Cre-encoding adenovirus (Fig. 3h). The *Cdh1<sup>A/A</sup>* MMEC line showed a similar dependency on actomyosin relaxation as the *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMEC subclones (Fig. 3i, j). Previously, E-cadherin has been shown to restrict RhoA activity by controlling both p190RhoGAP and p120-catenin signaling<sup>20–22</sup>. To determine if RhoA activity was also increased in E-cadherin-deficient MMECs during cell adhesion, we performed a RhoA activation pull-down assay. Indeed, *Cdh1<sup>A/A</sup>* MMECs had increased levels of GTP-bound RhoA which coincided with increased expression of total RhoA compared to WT MMECs (Fig. 3k, i and Supplementary Fig. 3a). *Cdh1<sup>A/A</sup>* MMECs also

blebbistatin. Scale bar, 20  $\mu$ m. **(e)** Western blot analysis of pSer<sup>473</sup> Akt, Akt, cleaved caspase 3 and actin (loading control) in *Wcre;Cdh1<sup>F/F</sup>;mTmG* subclones grown in the absence or presence of 10  $\mu$ M Y-27632. **(f,g)** Representative images **(f)** and quantification **(g)** of clonogenic assays with *Wcre;mTmG* (circles) and *Wcre;Cdh1<sup>F/F</sup>;mTmG* (squares) subclones grown in the presence or absence of 10  $\mu$ M Y-27632 or 10  $\mu$ M blebbistatin (7 days after seeding the cells). Data are of three independent experiments with 3 clones per experiment **(h)** Western blot analysis of WT FVB and *Cdh1<sup>A/A</sup>* MMECs stained for E-cadherin and actin (loading control). **(i,j)** Representative images **(i)** and quantification **(j)** of clonogenic assays with *Cdh1<sup>A/A</sup>* and WT control MMEC lines with or without 10  $\mu$ M Y-27632. Data are of three independent experiments **(k)** Representative images of Immunoblots of active RhoA pulldown assays and ser<sup>19</sup>myosin light chain phosphorylation (pMLC) from *Cdh1<sup>A/A</sup>* and WT control MMECs harvested 3 hours post seeding. **(l)** Quantification of active RhoA pulldown assays by densitometry normalized to the actin loading control. Data are of three independent experiments. All data are depicted as mean  $\pm$  standard deviation. All *p*-values were calculated using an unpaired two tailed t-test. Source data are provided as a Source Data file.

showed increased MLC expression and phosphorylation, confirming an overall increase in actomyosin contractility upon cell adhesion compared to WT MMECs. (Fig. 3k, l and Supplementary Fig. 3a-c). Together these results show that E-cadherin-deficient MMECs have aberrant actomyosin contractility during cell adhesion which needs to be reduced in order to allow their adhesion and survival.


### **Balanced actomyosin contractility is essential for survival**

Whereas E-cadherin-deficient MMECs require actomyosin relaxation in order to sustain cell adhesion and survival, progression of cell division requires actomyosin contraction<sup>23,24</sup>. We therefore hypothesized that too much actomyosin relaxation would hamper cell survival of E-cadherin-deficient MMECs. To examine this in more detail, we analyzed survival of E-cadherin-deficient MMECs subjected to increasing levels of actomyosin relaxation. We performed colony formation assays using concentration ranges of Blebbistatin (Fig. 4a, b) or the ROCK inhibitor H1152<sup>25</sup> (Fig. 4c, d). H1152 inhibits ROCK with increased specificity and potency compared to Y-27632. Both inhibitors readily rescued survival of E-cadherin-deficient MMECs at low concentrations, i.e. 0.5  $\mu$ M for Blebbistatin and 0.1  $\mu$ M for H1152 (Fig. 4a-d). Optimal concentrations permitting survival of E-cadherin-deficient MMECs were found at 5  $\mu$ M for Blebbistatin and 1  $\mu$ M for H1152. Importantly, higher concentrations of both compounds hampered survival of E-cadherin-deficient MMECs. Exposure of E-cadherin-deficient MMECs to various concentrations of H1152 reveals a dose dependent effect on MLC phosphorylation (Supplementary Fig. 4). The optimal concentration of H1152 only partially inhibited MLC phosphorylation indicating that too much relaxation is not tolerated. Altogether these results underscore the requirement of a critical balance in actomyosin contractility that mediates adhesion but does not hamper survival of E-cadherin-deficient MECs.

### **MYPT1 drives actomyosin relaxation and cell adhesion**


We recently found that protein-truncating mutations in *Ppp1r12a* (encoding MYPT1) drive ILC formation in mice<sup>26</sup>. MYPT1 regulates actomyosin contractility by acting as the regulatory subunit of the holoenzyme myosin light chain phosphatase MLCP which inhibits myosin light chain (MLC) activity<sup>27</sup>. Truncated MYPT1 lacks the PLK1 and LATS1 interaction domains involved in regulation of mitosis and retains the functional domains to bind PP1 and target pMLC<sup>28–30</sup>. Truncated MYPT1 also lacks the two inhibitory





**Figure 4: Balanced actomyosin contractility is essential for survival (a,b)** Representative images (a) and quantification (b) of clonogenic assays with *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMECs cultured with different concentrations of blebbistatin. Data are of three independent experiments with 3 clones per experiment. (c,d) Representative images (c) and quantification (d) of clonogenic assays with *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMECs cultured with different concentrations of H1152. Data are of three independent experiments with 3 clones per experiment. All data are depicted as mean ± standard deviation. Source data are provided as a Source Data file.

phosphorylation sites (T696 and T853) that are targeted by ROCK and cause auto-inhibition of MYPT1<sup>29</sup>. Therefore, we wondered if truncated MYPT1 could inhibit actomyosin contractility and thereby rescue adhesion of *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMECs upon Y-27632 withdrawal. To test this hypothesis, we transduced the E-cadherin-deficient *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMEC subclones with a lentivirus encoding doxycycline (dox)-inducible, Flag-tagged truncated MYPT1 (t-MYPT1) (Fig. 5a). Protein expression of t-MYPT1 was clearly detected 24hrs after adding dox and lost 48 hours after dox washout (Fig. 5b). Loss of t-MYPT1 significantly increased MLC activity, reflected by increased pMLC IF staining along the actin stress fibers confirming that t-MYPT1 reduces actomyosin contractility (Fig. 5c, d). In accordance with exposure to optimal concentrations of H1152 expression of tMYPT1 does not completely inhibit MLC phosphorylation in E-cadherin-deficient MMECs. Accordingly, the expression of t-MYPT1 also rescued cell adhesion and survival of *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMECs in the absence of Y-27632 (Fig. 5e, f). We further hypothesized that the absence of the ROCK-controlled inhibitory phosphorylation sites would increase the potency of t-MYPT1 as an inhibitor of actomyosin contractility (Fig. 5g).




**Figure 5: MYPT1 drives actomyosin relaxation and cell adhesion** (a) Schematic overview of the doxycycline (dox) inducible t-MYPT1 (MYPT1<sup>1-413</sup>) construct. (b) Western blot analysis of *Wcre;Cdh1<sup>FF</sup>;mTmG* MMECs transduced with dox-inducible Flag-tagged t-MYPT1 in the absence, presence or following washout of 2 mg/ml dox as stained for FLAG and actin (loading control). (c,d) IF staining (c) and quantification (d) of dox-inducible Flag-tagged t-MYPT1 *Wcre;Cdh1<sup>FF</sup>;mTmG* MMECs cultured in the presence of 2  $\mu$ g/ml dox or 50 hours post washout stained for phospho myosin light chain (pMLC), actin and Hoechst. Data are of 15 images per condition (e,f) Representative images (e) and quantification (f) of clonogenic assays with *Wcre;Cdh1<sup>FF</sup>;mTmG* MMECs expressing Dox-inducible Flag-tagged t-MYPT1 cultured with or without 2 mg/mL dox and/or 10  $\mu$ M Y-27632. Data are of three independent experiments with three clones per experiment (g) Schematic overview of full length MYPT1, t-MYPT1 and t-MYPT1 $\Delta$ PP1 (MYPT1<sup>92-413</sup>) displaying the PP1-recognition motif and the ankyrin repeats (ANK)

Indeed, overexpression of full length MYPT1 had a relatively modest effect on MLC phosphorylation and cell adhesion compared to t-MYPT1 (Fig. 5h-i, and Supplementary Fig. 4). To reduce actomyosin contractility, MYPT1 encompasses a N-terminal region containing a protein phosphatase 1 (PP1) recognition motif and seven Ankyrin repeats (ANK) that facilitate PP1 binding, all of which are retained in t-MYPT1<sup>27,31,32</sup>. PP1 acts as the catalytic subunit of MLCP and reduces actomyosin contractility by dephosphorylating Serine 19 of MLC<sup>32</sup>. Since the PP1 recognition motif of MYPT1 has been shown to drive PP1 activity upon binding of PP1<sup>32</sup>, we generated a t-MYPT1 variant lacking the PP1 recognition motif (t-MYPT1ΔPP1) (Fig. 5g). Stable expression of t-MYPT1 and t-MYPT1ΔPP1 showed that loss of the PP1 recognition domain impaired dephosphorylation of pMLC in *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMECs (Fig. 5h, i). Expression of t-MYPT1ΔPP1 also failed to rescue cell adhesion and survival of *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMECs in clonogenic survival assays (Fig. 5j, k and Supplementary Fig. 5). Overall, these data demonstrate that t-MYPT1 rescues cell adhesion and survival of *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMECs by PP1-mediated relaxation of actomyosin contractility.

### Collagen I does not support adhesion upon loss of E-cadherin

Since loss of E-cadherin impaired cell adhesion of primary MMECs *in vitro*, we next examined the impact of the extracellular matrix surrounding the E-cadherin-deficient MMECs. Upon Cre expression in 6-week old *Wcre;Cdh1<sup>F/F</sup>;mTmG* mice, GFP-marked E-cadherin-deficient MMECs extruded towards the basal lamina (Fig. 6a, zoom). These findings are in line with the observed extruded clusters of E-cadherin-deficient MMECs in the surrounding mammary fibrous stroma which we started to observe in 12-week and older *Wcre;Cdh1<sup>F/F</sup>;mTmG* mice (Fig. 1e, f). Remarkably, these clusters in the mammary fibrous stroma are surrounded by laminin (Fig. 6a). We therefore next examined cell adhesion and survival of E-cadherin-deficient MMECs on laminin-332, a component of the mammary basal lamina. Laminin-332-rich matrix derived from Rac-11P cells readily

domain, the leucizine zipper domain and inhibitory phosphorylation sites (T696 and T853). (h,i) IF staining (h) and quantification (i) of *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMECs transduced with MYPT1-wt, t-MYPT1, t-MYPT1ΔPP1 or GFP 48 hours post washout of 10 μM Y-27632 and stained for pMLC, actin and Hoechst. Data are of 15 images per condition. (j,k) Representative images (j) and quantification (k) of clonogenic assays with *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMECs transduced with t-MYPT1, t-MYPT1ΔPP1 or GFP cultured in the presence or absence of 10 μM Y-27632 (7 days after seeding the cells). Data are of three independent experiments with 3 clones per experiment. All data are depicted as mean ± standard deviation. All p-values were calculated using an unpaired two tailed t-test. Source data are provided as a Source Data file.



**Figure 6: Collagen I does not support adhesion upon loss of E-cadherin** (a) IF analysis of GFP (green), Laminin (red) and Keratin 8 (cyan) expression in mammary gland sections from 12-week-old *Wcre;mTmG* (top panels) and *Wcre;Cdh1<sup>FF</sup>;mTmG* mice (middle and bottom panels). Scale bar is 20  $\mu$ m (b,c) Representative images (b) and quantification (c) of clonogenic assays with *Wcre;Cdh1<sup>FF</sup>;mTmG* MMEC subclones seeded on laminin-coated wells or uncoated plastic wells. Data are of three independent experiments with 3 clones

supported cell adhesion and survival of *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMECs in the absence of Y-27632 or Blebbistatin and therefore likely supports survival of E-cadherin-deficient MMECs in the fibrous stroma (Fig. 5b, c). In comparison to laminin-332, collagen IV, another component of the basal lamina, induced a more modest increase in survival of E-cadherin-deficient MMECs (Supplementary Fig. 6). Yet, the mammary fibrous stroma is mainly characterized by the deposition of collagen I<sup>33</sup>. The clusters of E-cadherin-deficient MMECs, marked by GFP, in the mammary glands of *Wcre;Cdh1<sup>F/F</sup>;mTmG* mice were indeed surrounded by fibrous collagen (Fig. 6d and Supplementary Fig. 7). We therefore compared cell adhesion and survival of E-cadherin-deficient MMECs on laminin-332 with collagen I (Fig. 6e, f). In contrast to laminin-332, collagen I did not support adhesion and survival of E-cadherin-deficient MMECs despite expression of the collagen-receptor integrin  $\alpha 2\beta 1$  (Fig. 6e, f and Supplementary Fig. 8). Contrary to laminin-332, adhesion to collagen I has been reported to result in increased RhoA activity<sup>34,35</sup>. Indeed, a RhoA activation assay confirmed that *Cdh1<sup>Δ/Δ</sup>* MMECs on laminin-332 matrix have significantly decreased RhoA activity compared to cells on collagen I during cell adhesion (Fig. 6g-i). In line with these findings, survival of E-cadherin-deficient MMECs on collagen I could be rescued by expression of t-MYPT1 but not by t-MYPT1ΔPP1, which is unable to reduce actomyosin contractility (Fig. 6j, k). Overall these results highlight that collagen I impairs cell adhesion and survival of E-cadherin-deficient MMECs indicating that the collagen-rich mammary stroma may play an important role in preventing extruded E-cadherin-deficient MMECs from developing into an ILC.

## Relaxation of actomyosin contractility drives ILC formation

As actomyosin relaxation rescued survival of E-cadherin-deficient MMECs

per experiment. (d) GFP immunohistochemistry staining combined with a methylene blue staining (collagen). Scale bar is 20  $\mu$ M (e,f) Representative images (e) and quantification (f) of clonogenic assays with *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMEC subclones seeded on laminin-coated or collagen I-coated wells in the presence or absence of Y27632 (10  $\mu$ M) or blebbistatin (10  $\mu$ M). Data are of three independent experiments with 3 clones per experiment. (g-i) Immunoblots (g) and quantifications (h,i) of active RhoA pulldown assays from *Cdh1<sup>Δ/Δ</sup>* MMECs harvested 3 hours post plating on laminin- or collagen I-coated plates. Data are of three independent experiments. (j,k) Representative images (j) and quantification (k) of clonogenic assays with *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMECs transduced with t-MYPT1, t-MYPT1ΔPP1 or GFP cultured seeded on laminin-coated or collagen I-coated wells. Data are of three independent experiments with 3 clones per experiment. All data are depicted as mean  $\pm$  standard deviation. All *p*-values were calculated using an unpaired two tailed t-test. Source data are provided as a Source Data file.




on collagen I, it might also enable the development of ILC, which is typically marked by the massive accumulation of fibrous collagen<sup>8</sup>. We therefore examined whether the relaxation of actomyosin contractility could drive malignant transformation of E-cadherin-deficient MMECs *in vivo* and promote ILC formation in mice. We performed intraductal injections with lentiviruses encoding MYPT1, t-MYPT1, t-MYPTΔPP1 and empty control in mammary glands of *Wcre;Cdh1<sup>F/F</sup>* mice and determined tumor burden 20 weeks post-injection (Fig. 7a). As seen before, expression of t-MYPT1 consistently induced formation of classic mouse ILCs characterized by the lack of E-cadherin expression and an Indian file growth pattern in tumor-associated stroma (Fig. 7b, c)<sup>26</sup>. Expression of full-length MYPT1 also induced ILC formation, although tumors formed less frequently and were on average smaller in size. These results are in line with our previous observations that full-length MYPT1 displays reduced actomyosin relaxation activity compared to t-MYPT1 (Fig. 5). Importantly, expression of t-MYPTΔPP1, which is unable to induce actomyosin relaxation, failed to induce ILC formation in *Wcre;Cdh1<sup>F/F</sup>* mice (Fig. 7b). Altogether, these findings demonstrate that PP1-driven relaxation of actomyosin contractility by t-MYPT1 supports survival of E-cadherin-deficient MMECs in the collagen-rich mammary fibrous stroma, resulting in ILC development.

## Discussion

In this study we uncovered the direct consequences of E-cadherin inactivation in MMECs *in vivo*. We identified that MMECs upon loss of E-cadherin not only extrude to the lumen as previously reported, but also towards the basal lamina<sup>8,10</sup>. In contrast to cells that extrude towards the lumen, E-cadherin-deficient MMECs that extrude to the basal lamina do not undergo apoptosis. While extruded E-cadherin-deficient MMECs persist outside the basal lamina they do not form mammary tumors. However, because these cells do persist for a prolonged period of time they have the opportunity to gain additional mutations that allow tumor initiation. The accumulation and persistence of E-cadherin-deficient MMECs in the fibrous stroma might therefore explain the increased susceptibility of *CDH1* mutation carriers to develop ILC<sup>36–38</sup>.

Increased actomyosin contractility is generally considered to induce tumor cell invasion and migration, thereby promoting progression of established tumors towards metastatic disease<sup>39–41</sup>. In the present study,



**Figure 7: Relaxation of actomyosin contractility drives ILC formation** (a) Schematic representation of intraductal injections performed in *WapCre;Cdh1<sup>F/F</sup>* mice with high-titer lentiviruses produced from vectors encoding MYPT1-wt, t-MYPT1, t-MYPT1ΔPP1 or empty vector (EV). (b) Quantified tumor burdens of *Wcre;Cdh1<sup>F/F</sup>* females 20 weeks after intraductal injection of Lenti-EV ( $n = 16$  glands), Lenti-MYPT1-wt, ( $n = 12$  glands) Lenti-t-MYPT1 ( $n = 24$  glands) or Lenti-t-MYPT1ΔPP1 ( $n = 14$  glands). Data are depicted as mean  $\pm$  standard deviation.  $p$ -values were calculated using an unpaired two tailed t-test. (c) Representative images of tumor sections stained with H&E or stained for E-cadherin and CK8 and Collagen (Sirius red). Scale bar is 20  $\mu$ M. Source data are provided as a Source Data file.

we demonstrate that actomyosin relaxation promotes ILC development by enhancing adhesion and survival of E-cadherin-deficient MMECs. However, complete inhibition of actomyosin contractility in E-cadherin-deficient MMECs is not tolerated, indicating that there is a fine balance between too much contractility and too little. Taken together these findings indicate that the role of actomyosin contractility during tumorigenesis is context-dependent and may change depending on the microenvironment, tumor type and tumor stage.

Extrusion of E-cadherin-deficient MMECs into the mammary fibrous stroma

coincides with substantial changes in the extracellular matrix. Importantly, different ECM components have differential effects on the survival of E-cadherin-deficient MMECs. Survival of these cells is promoted by the basal lamina components, laminin-332 and collagen IV, but not by collagen I, which is the principle component of the fibrous stroma. Survival of E-cadherin-deficient MMECs on a collagen I matrix is critically dependent on actomyosin relaxation. This dependency can be explained by the differential effects of laminin-332 and collagen I on RhoA activity. It has been demonstrated that adhesion of integrin  $\alpha 3\beta 1$  to laminin-332 results in increased RAC1 activity, which indirectly inhibits RhoA via multiple mechanisms including activation of PAK and p190RhoGAP<sup>42–45</sup>. In contrast, adhesion of integrin  $\alpha 2\beta 1$  to collagen I has been shown to increase RhoA signaling<sup>35</sup>. Hence, the presence of fibrillar collagen might prevent spreading and proliferation of the extruded E-cadherin-deficient MMECs.

It is however well established that collagen I promotes invasion and migration of established tumor cells<sup>34,46,47</sup>. Moreover, the presence of large amounts fibrillar collagen is a hallmark of ILC<sup>5,8,48</sup>. It is therefore conceivable that collagen I might promote ILC progression once E-cadherin-deficient MECs have acquired mutations that allow for adhesion and survival on collagen I. These mutations might involve alterations that reduce actomyosin contractility or alterations (such as p53 loss) that enable E-cadherin-deficient MECs to survive high levels of actomyosin contractility<sup>49</sup>. Since fibroblasts, the main producers of collagen, infiltrate E-cadherin-deficient neoplastic lesions and massively accumulate in ILC<sup>6</sup>, they likely have conflicting roles depending on the stage of ILC development.

Our results show that relaxation of actomyosin contractility by MYPT1 promotes survival of E-cadherin-deficient MMECs on collagen I and leads to ILC formation. Accordingly, amplification of the *MYPT1* homolog *MYPT2* or hemizygous deletion of *MYH9* are frequently observed in human ILC<sup>26</sup>. The lack of homozygous *MYH9* deletions in ILC patients supports the notion E-cadherin-deficient cells do not tolerate complete inhibition of actomyosin contractility. Moreover, mutations in *RHOA* as well as RhoGEF and RhoGAP genes are common in *CDH1*-mutated diffuse-type gastric cancer<sup>50–52</sup>. At least several of the *RHOA* mutations have been identified as dominant-negative and lead to RhoA pathway inhibition<sup>53,54</sup>. Also the observed *CLDN18-ARHGAP* fusions result in inactivation of ROCK signaling and reduction of actomyosin contractility<sup>54</sup>. Alternatively, PI3K pathway mutations, which are very common in ILC<sup>36–38</sup>, may activate the RhoGTPase



Rac1 via non-canonical PI3K signaling, resulting in RhoA inhibition and reduced actomyosin contractility<sup>45,55</sup>. Altogether, these observations strongly support a dependency of ILC on actomyosin relaxation and raises the question to what extent the formation of E-cadherin-deficient tumors like diffuse gastric carcinoma are similarly dependent on actomyosin relaxation.

In conclusion, this study provides insights into ILC development by uncovering the direct consequences of E-cadherin inactivation in the mouse mammary gland and reveals actomyosin contractility as a critical barrier to ILC development. Moreover, the discovery of actomyosin regulation as a druggable oncogenic pathway might provide therapeutic opportunities to treat E-cadherin mutated cancers.

### **Acknowledgements**

We are grateful to Julia Houthuijzen, Chiara Brambilasca, Sam Cornelissen, Stefano Annunziato and Marjolijn Mertz, for providing technical suggestions and/or help with the experiments. We thank the NKI animal facility, the animal pathology facility and the digital microscopy facility for their expert technical support. Financial support was provided by the Dutch Cancer society (KWF: project 2015-7589), the Netherlands Organization for Scientific Research (NWO: Cancer Genomics Netherlands (CGCNL), VENI 016156012 (M.N.) and VICI 91814643 (J.J)), the European Research Council (ERC Synergy project CombatCancer (J.J.), ERC consolidator project Cancer-Recurrence 648804 (J.V.R.)) and the Doctor Josef Steiner Cancer Foundation (J.V.R.). This work is part of the Oncode Institute which is partly financed by the Dutch Cancer Society.

### **Author Contributions**

K.S., M.N., A.S., J.V.R. and J.J. designed experiments. K.S., M.N., D.S., V.R., A.P.D. and E.B. performed experiments. M.N. and J.J. supervised the study. K.S., M.N. and J.J. wrote the manuscript.

### **Competing Interests**

The authors declare no competing interests.

## Methods

### Generation of mice

*Wcre;Cdh1<sup>F/F</sup>;mTmG* mice were generated by intercrossing *Wcre;Cdh1<sup>F/F</sup>* mice<sup>13</sup> with *mTmG* reporter mice<sup>14</sup>. Mice were bred onto an FVB/N background and genotyped as described<sup>13,14</sup>. All animal experiments were approved by the Animal Ethics Committee of the Netherlands Cancer Institute and performed in accordance with institutional, national and European guidelines for Animal Care and Use.

### Intravital imaging

Mice were anesthetized using isoflurane (1.5% isoflurane/medical air mixture). A small incision was made on top of the 9th and the 10th mammary gland. The gland was mobilized and placed on a coverslip. The mouse is placed in a facemask with a custom designed imaging box. During imaging the mouse received 100µl/hr Nutrilex special 70/240 (Braun) subcutaneous. Imaging was performed on an inverted Leica SP8 multiphoton microscope with a chameleon Vision-S (Coherent Inc., Santa Clara, CA, [www.coherent.com](http://www.coherent.com)), equipped with four HyD detectors: HyD1 (<455nm), HyD2 (455–490nm), HyD3 (500–550nm) and HyD4 (560–650nm). Different wavelengths between 800nm and 960nm were used for excitation; collagen (second harmonic generation) was excited with a wavelength of 800nm and detected in HyD4. GFP and Tomato were excited with a wavelength of 960nm and detected in HyD1 and HyD2. Ducts were imaged every 20–30 minutes using a Z-step size of 5µm over a minimum period of 5 hours. All images were in 12 bit and acquired with a 25× (HCX IRAPO N.A. 0.95 WD 2.5 mm) water objective. Image analysis was performed manually using Leica application suite X and ImageJ.

### Intraductal injection of lentiviruses

Intraductal injections were performed as described<sup>56</sup>. Briefly, the mice (2–5 months of age) were anesthetized using ketamine/sedazine (100 and 10 mg/kg respectively) and hair was removed in the nipple area with a commercial hair removal cream. 18 µl of high-titer lentivirus mixed with 2 µl 0.2% Evans blue dye in PBS was injected in the fourth mammary glands by using a 34G needle. Mice were handled in a biological safety cabinet under a stereoscope. Lentiviral titers ranging from  $2 \times 10^8$  TU/mL to  $2 \times 10^9$

TU/mL were used. Animals were sacrificed at 20 weeks post-injection. The tumor burden of injected glands was determined as the ratio between the total tumor area and the area of the whole mammary gland, using Fiji (imageJ) software version 1.52n.

### Lentiviral vectors and virus production

Generation of the SIN.LV.SF-GFP-T2A-puro (GFP Fig 4H-L) and SIN.LV.SF-T2A-puro (Empty Vector Fig 4O) was described<sup>24</sup>. MYPT1 was isolated with Age1-Sal1 or Age1-Age1 overhangs and a 3' FLAG tag from cDNA derived from the NMuMG cell line RNA using Phusion Flash High-Fidelity DNA Polymerase (Thermo scientific). t-MYPT1 was isolated with Age1-Sal1 or BamH1-Age1 overhangs and a 3' FLAG tag from the *Ppp1r12a*<sup>ex1-9</sup> pBABE puro vector previously described<sup>26</sup> using Phusion Flash High-Fidelity DNA Polymerase (Thermo scientific). The cDNA fragments were then inserted into SIN.LV.SF<sup>57</sup> or SIN.LV.SF-T2A-puro to generate SIN.LV.SF-MYPT1 SIN.LV.SF-t-MYPT1, SIN.LV.SF-MYPT1-T2A-puro and SIN.LV.SF-tMYPT1-T2A-puro. MYPT1ΔPP1 was isolated with BamH1-Age1 or BamH1-Sal1 overhangs and a 3' FLAG tag from SIN.LV.SF tMYPT1 using Phusion Flash High-Fidelity DNA Polymerase. The cDNA fragments were then inserted into SIN.LV.SF or SIN.LV.SF-T2A-puro to generate SIN.LV.SF MYPT1ΔPP1 and SIN.LV.SF-MYPT1ΔPP1-T2A-puro.

The pINDUCER20<sup>58</sup> cassette (with a KRAS<sup>G12D</sup> construct) was isolated with Nhe1 and Sal1 overhangs using Phusion Flash High-Fidelity DNA Polymerase. The cDNA was inserted into a Nhe1 and Sal1 digested SIN.LV.SF vector to generate SIN.LV.SF pINDUCER20 KRAS<sup>G12D</sup>. tMYPT1 was isolated from SIN.LV.SF tMYPT1 with Sal1 and Age1 restriction enzymes. The Age1-Sal1 overhangs were subsequently blunted using Klenow (New England biolabs). The SIN.LV.SF pINDUCER20 KRAS<sup>G12D</sup> plasmid was digested with EcoRV to remove KRAS<sup>G12D</sup> and inserted with the blunted tMYPT1 cDNA described above to generate SIN.LV.SF pINDUCER20 tMYPT1. All primers are listed in Supplementary Table 1. All vectors were validated by Sanger sequencing. Concentrated lentiviral stocks were produced by transient co-transfection of four plasmids in 293T cells as described<sup>50</sup>. Viral titers were determined using the qPCR lentivirus titration kit from Abm (LV900).

### Cell culture

Primary mammary epithelial cells (MECs) were isolated from 10-15 week old

females as described<sup>59</sup> and cultured in Dulbecco's modified Eagle's medium (DMEM)-F12 (10565–018; Gibco) with 10% FBS, 1% penicillin-streptomycin, 5 ng/ml epidermal growth factor (EGF) (Sigma), 5ng/ml insulin (all from Life Technologies) and 5 ng/ml cholera toxin (Gentaur). Y-27632 (10  $\mu$ M, Abmole, M1817), Blebbistatin (10  $\mu$ M or as otherwise indicated, Sigma, B0560) or H1152 dihydrochloride (Tocris, 2414) was added to the cell culture medium when indicated. Experiments were performed with primary MEC clones until cell passage 25. Laminin producing Rac11P cells were cultured in DMEM (Life technologies) with 10% FBS, 1% penicillin-streptomycin.

### Colony formation assays

Mammary epithelial cells were plated at a density of 5000 cells per plate in 6 wells plate in the presence or absence of the indicated drugs (with the indicated concentration). For the inducible t-MYPT1 (Fig 5c-e) dox was added 24 hours before plating to induce expression of t-mypt1 at the time of plating. 7 days after plating the cells were fixated with 4% formaldehyde for 15 minutes and then stained with 0.5% crystal violet in a 25% methanol solution for at least 30 minutes. The plates were then washed 3 times with demi water to remove any remaining dye and dried at room temperature in the dark. Crystal violet stainings were imaged using the Gel count (Oxford Optronix) and it's corresponding software. Quantification was performed by dissolving the crystal violet in 10% acetic acid in demineralized water and measuring the absorbance at 590 nm. The absorbance was normalized to the indicated control samples.

### Immunofluorescence

Formalin-fixed and paraffin-embedded sections were processed as described<sup>6</sup> and incubated overnight at 4°C with GFP (1:200, Abcam #13970), Cytokeratin 8 (1:200, DSHB Troma-1), Cytokeratin 14 (1:200, Covance PRB-155P), pMLC (1:100, Cell Signaling #3671), E-cadherin (1:200, E-bioscience #610181), laminin (1:100, Abcam #11575), primary antibodies. Secondary antibodies anti-Rat-Alexa Fluor 647 (1:1000, Invitrogen #A21247), anti-Rabbit-Alexa Fluor 568 (1:1000, Invitrogen #A11011), anti-Rat-Alexa Fluor 568 (1:1000, Invitrogen #11077), anti-mouse-Alexa Fluor 488 (1:1000, Molecular Probes #A21141), anti-Mouse-Alexa Fluor 405 (1:100, Invitrogen #A31553) were incubated overnight at 4°C. Sections were subsequently stained with Hoechst (1:1000, Thermo Scientific #62249) for 5 min and mounted using Vectashield (Vector Laboratories H-1000). Cultured MMECs were fixed with 4% paraformaldehyde (PFA) and stained with a primary antibody against:

pMLC (1:100, Cell Signaling #3675), Hoechst (1:1000, Thermo Fischer, 62249), and Alexa Fluor™ 647 Phalloidin (Thermo Fisher, A22287). All images were acquired using a Leica TCS SP5 Confocal and analyzed using LAS AF Version 2.6.3 software. pMLC stainings were quantified using ImageJ and normalized to the GFP surface area.

### **Western blot analysis**

Protein lysates were made using one of two lysis buffers: 20 mM Tris-HCl pH 8.0, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.5% deoxycholate, 0.1% SDS in milli-Q or 50mM Tris pH 7.5, 10mM MgCl<sub>2</sub>, 0.5M NaCl, and 2% Igepal (MLC western blots), complemented with protease and phosphatase inhibitors (Roche) and quantified using the BCA protein assay kit (Pierce). Protein lysates were loaded on a 4-12% gel Bis-Tris gradient gel (Invitrogen) and transferred overnight onto nitrocellulose membrane (Bio-Rad) in 1x transfer buffer (25 mM Tris, 2 M Glycine, 20% methanol in demineralized water). Membranes were blocked in 5% nonfat dry milk or 5% BSA in TBS-T (pH 7.6, 20 mM Tris, 137 mM NaCl, 0.005% Tween-20 in demineralized water) and incubated overnight in 5% nonfat dry milk or 5% BSA in TBS-T with the following primary antibodies: E-cadherin (1:1000, Invitrogen, #13-1900), Cleaved caspase-3 (1:1000, Cell Signaling, #9661), AKT1 (1:1000, Cell Signaling #2938), phospho-AKT(Ser473) (1:1000, Cell Signaling, #4060), FLAG (1:1000, Sigma F7425), MLC (1:1000, Cell Signaling #3672), phospho MLC (Ser20) (1:1000 Abcam #ab2480), Tubulin (1:1000, Sigma, # T9026) and  $\beta$ -actin (1:20000, Sigma, #A5441). Membranes were washed three times with TBST and incubated with one of the following secondary antibodies: anti-Rabbit HRP (1:2000, DAKO, P0260), Anti-Mouse HRP (1:2000, DAKO, P0448), anti-Rat HRP(1:2000, Invitrogen, 62-9520) or anti-mouse IRDye 680nm (1:5000, Li-COR 926-32222) in 5% nonfat dry milk or 5% BSA in TBS-T for 1 hour at room temperature. Stained membranes were washed three times in TBS-T and then developed using ECL (Pierce 32209 or BioRad 170-5060) on films (Amersham), a Fusion FX7 edge (Vilber) or captured using the Li-Cor Odyssey Infrared Imaging System and analyzed using the Fusion FX7 software or Odyssey Application software version 3.0.16. Uncropped blots can be found in the Supplementary Fig. 9.

### **Histopathology**

Mouse tissues were formalin-fixed in 10% neutral buffered formalin for 48 hours, embedded in paraffin, sectioned and stained with hematoxylin and

eosin (H&E) or Masson's trichrome. IHC was performed as described<sup>60</sup>. GFP staining was performed by using Rabbit-anti GFP (1:1000 Abcam, ab6556). Secondary antibodies that were used are HRP anti-rabbit Envision (DAKO Cytomation, K4011). For the GFP, Methyl Blue dual staining the GFP staining was performed first the same way as described<sup>8</sup>. The samples were then treated with Bouin's fixative for 1 hour at 65 degrees. The samples were counterstained with Hematoxiline for 8 minutes, and rinsed in running tap water for 10 minutes. Samples were washed in demi water twice for 5 minutes and exposed to Phosphomolybdic acid for 5 minutes. Phosphomolybdic acid solution was allowed to run off the samples for 5 minutes and Methyl blue solution was added for 5 minutes. Samples were then washed in demi water for 5 minutes and washed in 1% acetic acid for 2 minutes. Samples were then mounted the same as described<sup>9</sup>. All slides were digitally processed using the Aperio ScanScope (Aperio, Vista, CA, USA) and captured using ImageScope software version 12.0.0 (Aperio).

### **Flow Cytometry**

MEC clones were collected in 1% BSA in 1X PBS and stained with antibodies against:  $\alpha 1$  Integrin (1:100, BD biosciences, 555001),  $\alpha 2$  Integrin (1:100, BD biosciences, 553858),  $\beta 1$  integrin-APC (1:50, Thermo Fischer, 17-0291-82), Cy5-Goat anti-Hamster (1:500 Jackson laboratories) and DAPI (1:20) to exclude dead cells. Samples were analyzed using a BD LSRFortessa Cell Analyzer with BD FACSDiva Software and analysed using FlowJo software.

### **RhoA activation assay**

15 Million cells were plated on regular plastic, collagen coated or laminin coated plates and incubated for 3 hours at 37 degrees. Cells were washed with PBS and lysed with the lysis buffer included in the RhoA activity assay kit (Cytoskeleton, BK036). Lysates were incubated with 30  $\mu$ G RhoThekin beads for 1 hour at 4 degrees while rotating. Samples were washed once with wash buffer and 20  $\mu$ L of 2x sample buffer (Invitrogen, NP0007 and NP0009) and was added. Samples were incubated at 95 degrees for 5 minutes, run on NuPAGE™ 4-12% Bis-Tris Protein Gels (Thermo Fisher, NP0321) and transferred overnight on 0,2  $\mu$ M nitrocellulose membranes (Bio-rad ,1620112) in transfer buffer (25 mM Tris, 2M Glycine, 20% methanol in demineralized water). Membranes were blocked in 5% nonfat dry milk in TBS-T (pH 7.6, 20 mM Tris, 137 mM NaCl, 0.005% Tween-20 in

demineralized water). Mouse anti RhoA antibody (1:500, included in kit) was incubated overnight in 0,5% nonfat dry milk in TBS-T. Membranes were washed 3 times in TBS-T and incubated with the secondary antibody rabbit anti-mouse HRP (1:2000, Dako, P0260) in 5% nonfat dry milk in TBS-T. Stained membranes were washed three times for 10-20 minutes in TBS-T and subsequently developed using ECL (Pierce, 32209). The signal intensities were measured by densitometry in ImageJ and normalized to actin loading controls.

### **Laminin and collagen coating**

The laminin coating was generated by letting RAC-11P<sup>61</sup> cells grown to complete confluence. The plates were washed with 1x PBS and incubated overnight with 20 mM EDTA in 1x PBS overnight. The RAC-11P cells were then removed as sheets by pipetting and washing with 1x PBS. The coated plates were then stored at 4 degrees in 1X PBS until used. Collagen I coating was performed using 100 µG/mL Rat tail Collagen I (Corning, 354249) in 20 mM acetic acid for 2 hours at 37 degrees followed by washing with 1x PBS to neutralize the acid. The coated plates were used immediately or stored at 4 degrees until use (no longer than 24 hours). Collagen IV coating was performed using 100 µG/mL collagen IV (Santa Cruz, sc-29010) in 0.05 N HCl for 1 hour at room temperature followed by washing with 1x PBS to neutralize the acid. The coated plates were used immediately or stored at 4 degrees until use.

### **Statistical analyses**


Graphpad Prism v7.03 was used to generate all graphs and perform the statistical analyses. Data are represented as mean and standard deviations. All *p*-values were calculated using an unpaired two tailed t-test.

### **Data availability statement**

Source data for Figures 1g,h, 2c, d, f, 3d, j, m, 4b, d, 5d, f, l, k, 6c, e, h, i, k, 7b and Supplementary Figures 3a-c, 4b and 6b can be found in the source data file. All other data supporting the findings of this study can be obtained from the corresponding authors upon reasonable request.




# Supplementary Figures




**Supplementary Figure 1: Immunofluorescence analysis of Beta-catenin and P120 catenin**  
(a) IF analysis of *Wcre;mTmG* and *Wcre;Cdh1<sup>FF</sup>;mTmG* female mice stained for beta-catenin, GFP and Hoechst. Scale bar is 40  $\mu$ M. (b) IF analysis of *Wcre;mTmG* and *Wcre;Cdh1<sup>FF</sup>;mTmG* female mice stained for p120-catenin, GFP, E-cadherin and Hoechst. Scale bar is 20  $\mu$ M.







**Supplementary Figure 2: E-cadherin loss increases actomyosin contractility** IF analysis of *Wcre;mTmG* and *Wcre;Cdh1<sup>fl</sup>;mTmG* female mice stained for pMLC, GFP and Hoechst. Scale bar is 20μM.




**Supplementary Figure 3: E-cadherin deficient MMECs have increased RhoA expression and myosin light chain activity (a-c)** Quantification of immunoblots of RhoA (a), pMLC (b) and MLC (c) by densitometry normalized to the actin loading control. Data are mean  $\pm$  standard deviation of three independent experiments.  $p$ -values were calculated using an unpaired two tailed t-test. Source data are provided as a Source Data file




**Supplementary Figure 4: Optimal ROCK inhibition only partially inhibits MLC phosphorylation (a)** Western blot analysis and Quantification of E-cadherin deficient MMECs exposed to various concentrations of H1152 for 1 hour post seeding stained for pMLC Ser19, MLC and actin. **(b)** Quantification of the amount of MLC phosphorylation. Ratios were normalized to Vehicle (0 nM H1152) for each replicate. Data are mean  $\pm$  s.d. of four independent experiments. Source data are provided as a Source Data file.




**Supplementary Figure 5: Expression levels of MYPT1 variants in MMECs.** Western blot analysis of FLAG tagged MYPT1-wt, t-MYPT1 and t-MYPT1ΔPP1 protein expression.  $\beta$ -actin was used as a loading control.



**Supplementary Figure 6: Collagen IV slightly increases survival of E-cadherin deficient MMECs.** Representative images (a) and Quantification (b) of clonogenic assays with *Wcre;Cdh1<sup>F/F</sup>;mTmG* MMECs seeded on collagen IV-coated wells. Data are mean  $\pm$  standard deviation of three independent experiments with 3 clones per experiment.  $p$ -values were calculated using an unpaired two tailed t-test. Source data are provided as a Source Data file.



**Supplementary Figure 7: Clusters of extruded E-cadherin deficient cells are surrounded by fibrillar collagen (a)** Still images derived from *in vivo* intravital imaging of the mammary gland of 8-week-old *Wcre;mTmG* and *Wcre;Cdh1<sup>F/F</sup>;mTmG* mice. GFP signal is visualized in green, mTomato in red and 2<sup>nd</sup> harmonic generation used to detect fibrillar collagen is visualized in magenta. Scale bar is 50  $\mu$ M.



**Supplementary Figure 8: Collagen Integrin expression on MMECs** (a) Schematic overview of the gating strategy. (b) FACS analysis of *Wcre;mTmG* and *Wcre;Cdh1<sup>fl/fl</sup>;mTmG* derived MMECs stained for integrin alpha 1 (CD49a), integrin alpha 2 (CD49b) and integrin beta-1 (CD29).

## **Supplementary tables (available online)**

### **Supplementary Table 1**

Overview of all primers used in this study for genotyping and cloning

## References

1. Birchmeier, W. & Behrens, J. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. *Biochim. Biophys. Acta* **1198**, 11–26 (1994).
2. Vleminckx, K., Vakaet, L., Mareel, M., Fiers, W. & van Roy, F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. *Cell* **66**, 107–119 (1991).
3. Behrens, J., Mareel, M. M., Van Roy, F. M. & Birchmeier, W. Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell-cell adhesion. *J. Cell Biol.* **108**, 2435–2447 (1989).
4. Vos, C. B. *et al.* E-cadherin inactivation in lobular carcinoma in situ of the breast: an early event in tumorigenesis. *Br. J. Cancer* **76**, 1131–1133 (1997).
5. Martinez, V. & Azzopardi, J. G. Invasive lobular carcinoma of the breast: incidence and variants. *Histopathology* **3**, 467–488 (1979).
6. Arpino, G., Bardou, V. J., Clark, G. M. & Elledge, R. M. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. *Breast Cancer Res. BCR* **6**, R149–156 (2004).
7. Vlug, E., Ercan, C., van der Wall, E., van Diest, P. J. & Derksen, P. W. B. Lobular breast cancer: pathology, biology, and options for clinical intervention. *Arch. Immunol. Ther. Exp. (Warsz.)* **62**, 7–21 (2014).
8. Boelens, M. C. *et al.* PTEN Loss in E-Cadherin-Deficient Mouse Mammary Epithelial Cells Rescues Apoptosis and Results in Development of Classical Invasive Lobular Carcinoma. *Cell Rep.* **16**, 2087–2101 (2016).
9. Derksen, P. W. B. *et al.* Somatic inactivation of E-cadherin and p53 in mice leads to metastatic lobular mammary carcinoma through induction of anoikis resistance and angiogenesis. *Cancer Cell* **10**, 437–449 (2006).
10. Boussadia, O., Kutsch, S., Hierholzer, A., Delmas, V. & Kemler, R. E-cadherin is a survival factor for the lactating mouse mammary gland. *Mech. Dev.* **115**, 53–62 (2002).
11. Chen, A. *et al.* E-cadherin loss alters cytoskeletal organization and adhesion in non-malignant breast cells but is insufficient to induce an epithelial-mesenchymal transition. *BMC Cancer* **14**, 552 (2014).
12. Shamir, E. R. *et al.* Twist1-induced dissemination preserves epithelial identity and requires E-cadherin. *J. Cell Biol.* **204**, 839–856 (2014).
13. Derksen, P. W. B. *et al.* Mammary-specific inactivation of E-cadherin and p53 impairs functional gland development and leads to pleomorphic invasive lobular carcinoma in mice. *Dis. Model. Mech.* **4**, 347–358 (2011).
14. Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L. & Luo, L. A global double-fluorescent Cre reporter mouse. *Genes. N. Y. N* **2000** **45**, 593–605 (2007).
15. Shibata, T., Kokubu, A., Sekine, S., Kanai, Y. & Hirohashi, S. Cytoplasmic p120<sup>ctn</sup> regulates the invasive phenotypes of E-cadherin-deficient breast cancer. *Am. J. Pathol.* **164**, 2269–2278 (2004).
16. Charras, G. & Paluch, E. Blebs lead the way: how to migrate without

lamellipodia. *Nat. Rev. Mol. Cell Biol.* **9**, 730–736 (2008).

17. Coleman, M. L. *et al.* Membrane blebbing during apoptosis results from caspase-mediated activation of ROCK I. *Nat. Cell Biol.* **3**, 339–345 (2001).
18. Perrais, M., Chen, X., Perez-Moreno, M. & Gumbiner, B. M. E-cadherin homophilic ligation inhibits cell growth and epidermal growth factor receptor signaling independently of other cell interactions. *Mol. Biol. Cell* **18**, 2013–2025 (2007).
19. Qian, X., Karpova, T., Sheppard, A. M., McNally, J. & Lowy, D. R. E-cadherin-mediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. *EMBO J.* **23**, 1739–1748 (2004).
20. Noren, N. K., Arthur, W. T. & Burridge, K. Cadherin engagement inhibits RhoA via p190RhoGAP. *J. Biol. Chem.* **278**, 13615–13618 (2003).
21. Noren, N. K., Niessen, C. M., Gumbiner, B. M. & Burridge, K. Cadherin engagement regulates Rho family GTPases. *J. Biol. Chem.* **276**, 33305–33308 (2001).
22. Anastasiadis, P. Z. *et al.* Inhibition of RhoA by p120 catenin. *Nat. Cell Biol.* **2**, 637–644 (2000).
23. Kümpfer, S. *et al.* Rho-associated kinase (ROCK) function is essential for cell cycle progression, senescence and tumorigenesis. *eLife* **5**, e12994 (2016).
24. Sorce, B. *et al.* Mitotic cells contract actomyosin cortex and generate pressure to round against or escape epithelial confinement. *Nat. Commun.* **6**, 8872 (2015).
25. Ikenoya, M. *et al.* Inhibition of rho-kinase-induced myristoylated alanine-rich C kinase substrate (MARCKS) phosphorylation in human neuronal cells by H-1152, a novel and specific Rho-kinase inhibitor. *J. Neurochem.* **81**, 9–16 (2002).
26. Kas, S. M. *et al.* Insertional mutagenesis identifies drivers of a novel oncogenic pathway in invasive lobular breast carcinoma. *Nat. Genet.* (2017). doi:10.1038/ng.3905
27. Ito, M., Nakano, T., Erdodi, F. & Hartshorne, D. J. Myosin phosphatase: structure, regulation and function. *Mol. Cell. Biochem.* **259**, 197–209 (2004).
28. Chiyoda, T. *et al.* LATS1/WARTS phosphorylates MYPT1 to counteract PLK1 and regulate mammalian mitotic progression. *J. Cell Biol.* **197**, 625–641 (2012).
29. Khromov, A., Choudhury, N., Stevenson, A. S., Somlyo, A. V. & Eto, M. Phosphorylation-dependent autoinhibition of myosin light chain phosphatase accounts for Ca<sup>2+</sup> sensitization force of smooth muscle contraction. *J. Biol. Chem.* **284**, 21569–21579 (2009).
30. Yamashiro, S. *et al.* Myosin phosphatase-targeting subunit 1 regulates mitosis by antagonizing polo-like kinase 1. *Dev. Cell* **14**, 787–797 (2008).
31. Ichikawa, K., Ito, M. & Hartshorne, D. J. Phosphorylation of the large subunit of myosin phosphatase and inhibition of phosphatase activity. *J. Biol. Chem.* **271**, 4733–4740 (1996).
32. Tanaka, J. *et al.* Interaction of myosin phosphatase target subunit 1 with the catalytic subunit of type 1 protein phosphatase. *Biochemistry* **37**, 16697–16703



(1998).

33. Polyak, K. & Kalluri, R. The role of the microenvironment in mammary gland development and cancer. *Cold Spring Harb. Perspect. Biol.* **2**, a003244 (2010).
34. Egeblad, M., Rasch, M. G. & Weaver, V. M. Dynamic interplay between the collagen scaffold and tumor evolution. *Curr. Opin. Cell Biol.* **22**, 697–706 (2010).
35. Zhou, H. & Kramer, R. H. Integrin engagement differentially modulates epithelial cell motility by RhoA/ROCK and PAK1. *J. Biol. Chem.* **280**, 10624–10635 (2005).
36. Ciriello, G. *et al.* Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. *Cell* **163**, 506–519 (2015).
37. Desmedt, C. *et al.* Genomic Characterization of Primary Invasive Lobular Breast Cancer. *J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.* **34**, 1872–1881 (2016).
38. Michaut, M. *et al.* Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. *Sci. Rep.* **6**, 18517 (2016).
39. Rodriguez-Hernandez, I., Cantelli, G., Bruce, F. & Sanz-Moreno, V. Rho, ROCK and actomyosin contractility in metastasis as drug targets. *F1000Research* **5**, (2016).
40. Rath, N. *et al.* Rho kinase inhibitor AT13148 blocks pancreatic ductal adenocarcinoma invasion and tumor growth. *Cancer Res.* **78**, 3321–3336 (2018).
41. Narumiya, S., Tanji, M. & Ishizaki, T. Rho signaling, ROCK and mDia1, in transformation, metastasis and invasion. *Cancer Metastasis Rev.* **28**, 65–76 (2009).
42. Bustos, R. I., Forget, M.-A., Settleman, J. E. & Hansen, S. H. Coordination of Rho and Rac GTPase function via p190B RhoGAP. *Curr. Biol. CB* **18**, 1606–1611 (2008).
43. Rosenfeldt, H., Castellone, M. D., Randazzo, P. A. & Gutkind, J. S. Rac inhibits thrombin-induced Rho activation: evidence of a Pak-dependent GTPase crosstalk. *J. Mol. Signal.* **1**, 8 (2006).
44. Alberts, A. S., Qin, H., Carr, H. S. & Frost, J. A. PAK1 negatively regulates the activity of the Rho exchange factor NET1. *J. Biol. Chem.* **280**, 12152–12161 (2005).
45. Guilluy, C., Garcia-Mata, R. & Burridge, K. Rho protein crosstalk: another social network? *Trends Cell Biol.* **21**, 718–726 (2011).
46. Nguyen-Ngoc, K.-V. *et al.* ECM microenvironment regulates collective migration and local dissemination in normal and malignant mammary epithelium. *Proc. Natl. Acad. Sci. U. S. A.* **109**, E2595–2604 (2012).
47. Provenzano, P. P. *et al.* Collagen reorganization at the tumor-stromal interface facilitates local invasion. *BMC Med.* **4**, 38 (2006).
48. McCart Reed, A. E., Kutasovic, J. R., Lakhani, S. R. & Simpson, P. T. Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics. *Breast Cancer Res. BCR* **17**, 12 (2015).

49. Schackmann, R. C. J. *et al.* Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. *J. Clin. Invest.* **121**, 3176–3188 (2011).
50. Kakiuchi, M. *et al.* Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. *Nat. Genet.* **46**, 583–587 (2014).
51. Wang, K. *et al.* Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. *Nat. Genet.* **46**, 573–582 (2014).
52. Bass, A. J. *et al.* Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* **513**, 202–209 (2014).
53. García-Mata, R. *et al.* Analysis of activated GAPs and GEFs in cell lysates. *Methods Enzymol.* **406**, 425–437 (2006).
54. Nishizawa, T. *et al.* DGC-specific RHOA mutations maintained cancer cell survival and promoted cell migration via ROCK inactivation. *Oncotarget* **9**, 23198–23207 (2018).
55. Cain, R. J. & Ridley, A. J. Phosphoinositide 3-kinases in cell migration. *Biol. Cell* **101**, 13–29 (2009).
56. Annunziato, S. *et al.* Modeling invasive lobular breast carcinoma by CRISPR/Cas9-mediated somatic genome editing of the mammary gland. *Genes Dev.* **30**, 1470–1480 (2016).
57. Montini, E. *et al.* The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. *J. Clin. Invest.* **119**, 964–975 (2009).
58. Meerbrey, K. L. *et al.* The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. *Proc. Natl. Acad. Sci. U. S. A.* **108**, 3665–3670 (2011).
59. Ewald, A. J., Brenot, A., Duong, M., Chan, B. S. & Werb, Z. Collective epithelial migration and cell rearrangements drive mammary branching morphogenesis. *Dev. Cell* **14**, 570–581 (2008).
60. Henneman, L. *et al.* Selective resistance to the PARP inhibitor olaparib in a mouse model for BRCA1-deficient metaplastic breast cancer. *Proc. Natl. Acad. Sci. U. S. A.* **112**, 8409–8414 (2015).
61. Delwel, G. O. *et al.* Expression and function of the cytoplasmic variants of the integrin alpha 6 subunit in transfected K562 cells. Activation-dependent adhesion and interaction with isoforms of laminin. *J. Biol. Chem.* **268**, 25865–25875 (1993).